Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

FDA grants Fast Track Designation to AAVantgarde's AAVB-039 gene therapy for Stargardt disease, advancing development for this rare cause of vision loss.
April 28, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

AAVantgarde Bio appoints Rasmus Holm-Jorgensen as CFO to support growth and advance AAV gene therapies for inherited retinal diseases.